HC Wainwright Reiterates “Buy” Rating for Tango Therapeutics (NASDAQ:TNGX)
MarketBeatHC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Tango Therapeutics in a report on Monday.
HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Tango Therapeutics in a report on Monday.